Paul Hallenbeck

Company: Seneca Therapeutics Inc.

Job title: Chief Scientific Officer

Seminars:

Assessing the Benefits & Challenges of Intravenous Delivery of Oncolytic Viruses 11:00 am

How can we continue to deliver the virus intravenously? How can we overcome the body clearing the virus when delivered intravenously? What is the best way to conceal the virus in the bloodstream to avoid clearing and allowing it to cross into the tumor? What are the strategies to enhance viral circulation, evasion of neutralizing…Read more

day: Day One